Acute Pain & Procedural Sedation — Part 4: Specific Pain Scenarios, Discharge Management & Quality Metrics
Renal colic, fractures, headache, sickle cell crisis, burns, pediatric procedural pain, geriatric considerations, discharge multimodal prescribing, opioid alternatives, PDMP requirements, and quality metrics.
7. Specific Pain Scenarios
The following sections address evidence-based analgesic approaches for common ED pain presentations that benefit from targeted multimodal strategies. Each scenario emphasizes condition-specific first-line therapies, appropriate escalation pathways, and pitfalls to avoid.1 2
7.1 Renal Colic
Renal colic is one of the most severe pain presentations encountered in the ED. Evidence strongly supports an NSAID-first approach, with several randomized controlled trials and meta-analyses demonstrating that NSAIDs are equivalent or superior to opioids for renal colic pain, with significantly fewer adverse effects.1 3 4
7.1.1 Recommended Analgesic Approach
| Step | Agent | Dose | Evidence/Rationale |
|---|---|---|---|
| First-line | Ketorolac IV | 15–30 mg IV (15 mg in elderly or renal caution) | Multiple meta-analyses show NSAIDs are equivalent to opioids for renal colic with less nausea and vomiting; NSAIDs address the prostaglandin-mediated ureteral spasm and renal capsule distension that drive colic pain |
| First-line (alternative) | IV lidocaine | 1.5 mg/kg IV over 10 minutes | Randomized trials demonstrate efficacy equivalent to morphine for renal colic; particularly useful when NSAIDs are contraindicated (renal impairment, GI bleeding risk) |
| Adjunct | Acetaminophen IV | 1000 mg IV over 15 minutes | Additive analgesic effect with ketorolac; safe and effective as part of multimodal approach |
| Second-line | Opioid (if needed) | Fentanyl 0.5–1 mcg/kg IV or morphine 0.05–0.1 mg/kg IV | Reserve for pain refractory to ketorolac + acetaminophen + lidocaine; avoid as first-line due to nausea, sedation, and less effective treatment of underlying mechanism |
| Adjunct | Ondansetron | 4 mg IV | Treat nausea/vomiting (common with renal colic itself and with opioid use) |
| Smooth muscle relaxant | Tamsulosin | 0.4 mg PO (medical expulsive therapy for stones 5–10 mm) | Modest benefit for stone passage; controversial but widely used; more effective for distal ureteral stones |
7.1.2 Key Principles
- Avoid opioids as the first-line treatment. NSAIDs target the mechanism of pain (prostaglandin-mediated ureteral smooth muscle spasm and renal capsule distension); opioids do not.
- IV lidocaine is an excellent option when NSAIDs are contraindicated.
- Reassess within 30 minutes. If pain is refractory, add sequential agents (multimodal ladder).
- Renal colic with UTI signs (fever, pyuria) represents an obstructed infected kidney — an emergency requiring urology consultation and drainage, not simply more analgesia.
7.2 Fractures
Fracture pain management is a paradigm case for multimodal, opioid-sparing analgesia. Regional anesthesia, when available, should be considered the cornerstone of fracture analgesia.1 2 5
7.2.1 Recommended Approach by Fracture Location
| Fracture | First-Line Regional Anesthesia | Systemic Adjuncts | Notes |
|---|---|---|---|
| Hip fracture | Fascia iliaca compartment block (FICB) — 30–40 mL bupivacaine 0.25% or ropivacaine 0.2% | Acetaminophen 1000 mg IV/PO + ketorolac 15 mg IV (if no renal impairment) | FICB should be performed at triage or as soon as diagnosed; reduces opioid requirements by 50–70%; improves mobilization; decreases delirium in elderly |
| Femoral shaft fracture | Femoral nerve block — 15–20 mL bupivacaine 0.25% | Acetaminophen + NSAID | Ensure quadriceps weakness is expected; fall prevention measures |
| Distal radius fracture | Hematoma block — 10–15 mL lidocaine 1–2% into fracture hematoma | Acetaminophen + ibuprofen 400–600 mg PO | Hematoma block alone may suffice for closed reduction; supplement with procedural sedation (propofol or ketamine) if complex reduction needed |
| Ankle fracture | Ankle block (5-nerve block) or hematoma block | Acetaminophen + NSAID | Ankle block provides complete foot and ankle anesthesia; excellent for reduction |
| Rib fractures (unilateral, multiple) | Serratus anterior plane block (lateral ribs) or erector spinae plane block (posterior ribs) — 20–30 mL ropivacaine 0.2–0.375% | Acetaminophen + ketorolac + SDK (ketamine 0.1–0.3 mg/kg IV) | Rib fracture regional blocks dramatically improve inspiratory effort and cough; reduce opioid use; decrease pulmonary complications; consider catheter placement for continuous infusion if multiple fractures |
| Humeral fracture (proximal) | Interscalene block — 10–15 mL bupivacaine 0.25% | Acetaminophen + NSAID | Warn patient about phrenic nerve palsy; avoid bilateral or in patients with respiratory compromise |
| Digital fractures | Digital nerve block (ring block or transthecal) — 2–4 mL lidocaine 1–2% | None needed if block adequate | WALANT technique (with epinephrine) excellent for digital procedures |
7.2.2 Fracture Pain Protocol Summary
- Immediate: Splinting and immobilization (reduces pain significantly by preventing motion at fracture site)
- Early: Regional anesthesia if available and appropriate
- Systemic multimodal: Acetaminophen + NSAID (ketorolac or ibuprofen)
- Adjunct if needed: Subdissociative-dose ketamine (0.1–0.3 mg/kg IV) or opioid (fentanyl 0.5–1 mcg/kg IV)
- Reduction: Procedural sedation (propofol or ketamine) or regional anesthesia if not already performed
7.3 Headache (Primary Headache/Migraine)
Headache is one of the most common ED pain presentations. The evidence-based approach to primary headache (migraine, tension-type) emphasizes dopamine antagonists and NSAIDs as first-line therapy, with opioids playing no role in standard management. Opioids are associated with increased return visits, medication overuse headache, and inferior outcomes compared with first-line therapies.1 6 7
7.3.1 First-Line Migraine/Primary Headache Protocol
| Step | Agent | Dose | Route | Evidence |
|---|---|---|---|---|
| 1. Dopamine antagonist | Metoclopramide | 10–20 mg | IV over 15 min | First-line; provides both antiemetic and analgesic effects; NNT ~3 for headache relief; high-quality RCT evidence |
| OR | Prochlorperazine | 10 mg | IV over 2 min | Similar efficacy to metoclopramide; may be slightly more effective in some studies; extrapyramidal side effects are the primary concern |
| 2. Antihistamine (adjunct) | Diphenhydramine | 25–50 mg | IV | Reduces risk of akathisia and extrapyramidal symptoms from dopamine antagonists; provides mild sedation and additional analgesia; often given as routine co-administration |
| 3. NSAID | Ketorolac | 15–30 mg | IV | Effective for migraine pain; additive benefit with dopamine antagonist |
| 4. Fluid bolus | Normal saline | 500–1000 mL | IV | Dehydration is common with migraine (vomiting, oral intake intolerance); address volume depletion |
| 5. Dexamethasone | Dexamethasone | 10 mg | IV | Reduces headache recurrence within 72 hours (NNT ~9); does not improve acute headache but prevents bounce-back; administer before discharge |
7.3.2 Nerve Blocks for Headache
| Block | Technique | Indication | Evidence |
|---|---|---|---|
| Greater occipital nerve (GON) block | Patient seated; palpate the occipital protuberance; the GON is located approximately one-third of the distance from the occipital protuberance to the mastoid process along the superior nuchal line; inject 2–3 mL bupivacaine 0.5% with or without 20–40 mg triamcinolone | Occipital headache, migraine, tension-type headache, cluster headache (adjunct) | Multiple RCTs demonstrate significant headache relief; 60–80% response rate; onset within 15 minutes; effect may last days to weeks |
| Sphenopalatine ganglion (SPG) block | Patient supine; insert a cotton-tipped applicator soaked in lidocaine 4% or bupivacaine 0.5% through the nostril along the floor of the nasal cavity until it reaches the posterior nasopharynx (approximately to the level of the middle turbinate); hold for 10–15 minutes; bilateral application; alternatively, use the SphenoCath or Tx360 device | Migraine, cluster headache, trigeminal neuralgia, post-dural puncture headache | Emerging evidence from multiple small RCTs; provides rapid relief with minimal adverse effects; NNT approximately 3–4 for migraine relief; well-tolerated; can be repeated |
7.4 Sickle Cell Vaso-Occlusive Crisis (VOC)
Sickle cell vaso-occlusive crisis represents a unique and challenging ED pain management scenario. Patients with sickle cell disease experience severe, recurrent pain that is often undertreated due to provider bias and unfamiliarity with appropriate dosing. Evidence-based guidelines emphasize aggressive, individualized opioid analgesia with a multimodal approach.1 8 9
7.4.1 VOC Pain Management Protocol
| Step | Action | Detail |
|---|---|---|
| Time zero | Triage as emergent | VOC pain should be treated as an acute pain emergency; target time-to-analgesic <30 minutes from arrival (ideally <15 minutes) |
| Rapid assessment | Assess severity and complication screening | Pain score (NRS); vital signs; evaluate for acute chest syndrome, splenic sequestration, stroke, aplastic crisis, infection; obtain CBC, reticulocyte count, metabolic panel, type and screen if severe |
| First-line opioid | Morphine 0.1–0.15 mg/kg IV or Hydromorphone 0.015–0.02 mg/kg IV | Dose based on patient’s weight; use the higher end of the dosing range for opioid-tolerant patients; many patients have individualized pain protocols — check the medical record |
| Reassess at 15–30 min | Repeat opioid dose if NRS >4 | Repeat the same dose or a supplemental 50% dose every 15–30 minutes until adequate pain control or dose limit reached |
| Multimodal adjuncts | Ketorolac 15–30 mg IV + Acetaminophen 1000 mg IV | Add non-opioid agents to reduce total opioid requirement; NSAIDs effective for the inflammatory component of VOC |
| Ketamine adjunct | SDK 0.1–0.3 mg/kg IV over 15 min | For opioid-refractory pain; NMDA antagonism may address central sensitization that develops in chronic pain states; evidence supports reduced opioid consumption when ketamine is added |
| IV fluids | Normal saline at 1–1.5× maintenance | Avoid overhydration (risk of acute chest syndrome); maintain euvolemia |
| PCA consideration | Patient-controlled analgesia | For patients requiring repeated parenteral dosing or anticipated admission; PCA provides superior pain control and patient autonomy; typical morphine PCA: demand dose 1–2 mg, lockout 6–10 min, no basal rate for opioid-naive; hydromorphone PCA: demand dose 0.2–0.4 mg, lockout 6–10 min |
7.4.2 Key Principles for Sickle Cell Pain
| Principle | Rationale |
|---|---|
| Use individualized protocols | Many patients have institution-specific or patient-specific pain plans developed by their hematologist; check the medical record and honor these plans |
| Do not under-dose | Patients with sickle cell disease often have significant opioid tolerance; standard dosing may be inadequate; base dosing on the patient’s chronic opioid requirements |
| Believe the patient’s pain report | Sickle cell pain cannot be objectively verified; provider disbelief is a well-documented barrier to care; systematic bias leads to longer wait times and lower analgesic doses for sickle cell patients |
| Avoid meperidine (Demerol) | Accumulation of the toxic metabolite normeperidine causes seizures; meperidine should never be used for sickle cell crisis |
| Screen for complications | Every VOC is an opportunity to screen for acute chest syndrome (CXR if any respiratory symptoms, fever, or new hypoxia), stroke, and infection |
| Disposition | Discharge criteria: pain adequately controlled on oral medications, able to tolerate oral fluids, no evidence of complications; admit if pain uncontrolled, if any acute complications, or if PCA is required |
7.5 Burns
Burn pain management requires consideration of both the acute injury pain and the procedural pain associated with wound care, debridement, and dressing changes. Burns cause a combination of nociceptive and neuropathic pain that often requires aggressive multimodal therapy.1 2 10
7.5.1 Burn Pain Management by Severity
| Burn Severity | Pain Management Approach |
|---|---|
| Minor (superficial partial thickness, <10% TBSA) | Topical: cool running water for 20 minutes (within 3 hours of injury); silver sulfadiazine or non-adherent dressing; oral: acetaminophen + ibuprofen; opioids for breakthrough pain (oxycodone 5 mg PO); topical lidocaine preparations may help |
| Moderate (deep partial thickness, 10–20% TBSA) | IV access; ketorolac 15–30 mg IV + acetaminophen 1000 mg IV; opioid: fentanyl 0.5–1 mcg/kg IV (titrate) or morphine; subdissociative ketamine (0.1–0.3 mg/kg IV) for refractory pain; regional anesthesia if anatomically feasible |
| Severe (full thickness or >20% TBSA) | Aggressive IV opioid titration (fentanyl or morphine); ketamine 0.1–0.3 mg/kg IV for analgesic adjunct; consider ketamine dissociative sedation for debridement; burn center consultation and transfer |
| Wound care and dressing changes | Procedural: ketamine (subdissociative or dissociative doses depending on severity); nitrous oxide; opioid pre-medication 15–30 min before procedure; topical anesthesia to wound bed |
7.5.2 Ketamine for Burn Pain
Ketamine is particularly valuable for burn pain management:10
- Subdissociative doses (0.1–0.3 mg/kg IV) provide excellent background analgesia
- Dissociative doses (1–2 mg/kg IV) provide ideal sedation for painful dressing changes and debridement
- Does not cause respiratory depression (critical in patients with potential inhalation injury who require close airway monitoring)
- Maintains hemodynamic stability (important in patients who may be volume-depleted)
- NMDA antagonism addresses both nociceptive and neuropathic components of burn pain
- IM route (4–5 mg/kg) available for patients without IV access in prehospital or mass casualty settings
7.6 Pediatric Procedural Pain: A Comprehensive Approach
Pediatric pain management in the ED requires a systematic, age-appropriate approach that combines non-pharmacologic interventions, topical anesthesia, and procedural sedation when needed. Children are particularly vulnerable to oligoanalgesia and procedural distress, and studies consistently show that pediatric pain is undertreated more often than adult pain.11 12 13
7.6.1 Non-Pharmacologic Interventions
| Strategy | Age Range | Application | Evidence |
|---|---|---|---|
| Positioning (comfort hold) | All ages | Parent holds child in their lap facing parent or with child’s back against parent’s chest; allows the procedure to be performed while the child is comforted by parent | High-quality evidence that parental presence and comfort positioning reduce distress; eliminates need for physical restraint in many cases |
| Breastfeeding/sucrose | Neonates and infants (<12 months) | Breastfeeding during the procedure; or sucrose solution (24% sucrose, 0.5–1 mL on pacifier) 2 minutes before procedure | Cochrane review evidence for pain reduction during minor procedures (heel sticks, venipuncture); NNT ~3 |
| Distraction | Toddlers to adolescents | Bubbles, light-up toys, tablets/videos (age-appropriate), virtual reality (emerging evidence), music, interactive games, guided imagery | Moderate-to-high evidence that distraction reduces procedural pain and distress; most effective when age-appropriate and actively engaging |
| Child life specialist | All ages | Trained professionals who provide preparation, education, coping strategies, and procedural support | Evidence supports reduced distress and improved procedure completion; considered standard of care in pediatric EDs |
| Preparation and honesty | School-age and adolescents | Explain the procedure in age-appropriate language; be honest about expected sensations; give the child choices where possible (which arm for IV) | Reduces anxiety and improves coping; deception (“it won’t hurt”) is counterproductive and destroys trust |
| Swaddling/facilitated tucking | Neonates and young infants | Snug wrapping of extremities with hands near face during procedures | Reduces physiologic stress responses and behavioral pain indicators |
7.6.2 Pediatric Topical Anesthesia Protocol
| Procedure | Topical Agent | Application Time | Notes |
|---|---|---|---|
| IV cannulation | LMX-4 (lidocaine 4% cream) or EMLA cream | LMX-4: 30 minutes; EMLA: 60 minutes | Apply at triage over anticipated IV sites; cover with occlusive dressing; if no time: J-Tip device (needleless lidocaine delivery, 1–2 seconds), vapocoolant spray (immediate but brief) |
| Laceration repair | LET gel (lidocaine 4%/epinephrine 0.1%/tetracaine 0.5%) | 20–30 minutes | Apply directly into wound and surrounding skin; cover with occlusive dressing; blanching of wound edges indicates adequate absorption; supplement with buffered injectable lidocaine if needed |
| Lumbar puncture | EMLA cream | 60–90 minutes | Apply over L3-L4 interspace; deeper anesthesia needed (90 minutes preferred); infiltrate subcutaneously with buffered lidocaine before needle insertion |
| Abscess I&D | LET gel (around incision site) + consider procedural sedation for larger abscesses | 20–30 minutes | LET alone may be inadequate for deep abscesses; combine with injectable local anesthesia and/or procedural sedation |
| Blood draw/venipuncture | LMX-4 or EMLA or J-Tip or vapocoolant spray | Variable | J-Tip is fastest (no wait); vapocoolant second fastest; topical creams require advance planning |
7.6.3 Pediatric Intranasal Agents
Intranasal medication administration via the mucosal atomization device (MAD) is a cornerstone of pediatric ED pain management, providing rapid, painless, needle-free delivery:12 13
| Agent | Dose | Indication | Onset | Duration | Notes |
|---|---|---|---|---|---|
| Fentanyl | 1.5–2 mcg/kg (max 100 mcg per nostril) | Acute pain (fractures, burns, significant injuries) | 5–10 min | 30–60 min | First-line IN analgesic for children with moderate-to-severe pain; equivalent to IV morphine in RCTs; painless |
| Ketamine | 0.5–1 mg/kg | Acute pain; anxiolysis before procedures | 5–10 min | 30–60 min | Use 100 mg/mL concentration to minimize volume; excellent for fracture pain |
| Midazolam | 0.3–0.5 mg/kg (max 10 mg) | Anxiolysis before procedures; seizure treatment | 5–10 min | 30–60 min | Use 5 mg/mL concentration; burning sensation is common (bitter taste); provide a flavored drink afterward |
| Dexmedetomidine | 2–4 mcg/kg | Pre-procedural sedation; MRI sedation | 20–30 min | 60–90 min | Longer onset; used when time allows for non-painful procedures |
7.7 Geriatric Pain Management Considerations
Elderly patients represent a uniquely vulnerable population for both undertreated pain and analgesic adverse effects. Physiologic changes of aging affect drug pharmacokinetics and pharmacodynamics, necessitating dose adjustments and heightened monitoring.14 15
| Principle | Detail |
|---|---|
| Pain assessment | Use age-appropriate scales; PAINAD for patients with dementia; do not assume elderly patients have less pain; cognitively impaired patients may exhibit behavioral pain indicators (agitation, grimacing, withdrawal) rather than verbal complaints |
| Acetaminophen | Preferred first-line agent; safe at standard doses (reduce to max 2000 mg/day if hepatic impairment or weight <50 kg) |
| NSAIDs | Use with extreme caution; increased risk of GI bleeding (2–4× higher than younger adults), acute kidney injury, fluid retention, and cardiovascular events; if used, lowest dose for shortest duration; ketorolac max 15 mg IV in elderly; avoid in patients on anticoagulants |
| Opioids | Start at 25–50% of standard adult doses; titrate slowly; use fentanyl (short-acting, fewer active metabolites) over morphine (active metabolite M6G accumulates in renal impairment); avoid meperidine (normeperidine seizure risk); monitor for respiratory depression, constipation, sedation, delirium |
| Subdissociative ketamine | Safe and effective in elderly; may be particularly useful for reducing opioid exposure; use lower end of dosing range (0.1–0.15 mg/kg IV); slower infusion |
| Regional anesthesia | First-line for hip fractures (FICB); highly effective and avoids systemic analgesic risks; reduces delirium incidence in elderly hip fracture patients; consider for rib fractures (reduces pneumonia risk) |
| Delirium risk | All centrally-acting analgesics can contribute to delirium in elderly patients; minimize benzodiazepines (strongest independent risk factor for delirium); use multimodal non-opioid approaches when possible; monitor mental status as part of pain assessment |
| Fall risk | Opioids, benzodiazepines, and gabapentinoids increase fall risk; consider this when choosing agents and when planning discharge |
8. Discharge Pain Management
Effective discharge pain management is critical for patient outcomes, satisfaction, and prevention of ED return visits. The discharge plan should continue the multimodal approach used in the ED, emphasizing non-opioid therapies with opioids reserved for breakthrough pain.1 2 16
8.1 Multimodal Discharge Prescribing
| Component | Recommendation | Duration |
|---|---|---|
| Acetaminophen | 500–1000 mg PO every 6 hours (scheduled, not PRN) | 3–7 days depending on condition |
| NSAID | Ibuprofen 400–600 mg PO every 6–8 hours WITH FOOD, or naproxen 250–500 mg PO every 12 hours | 3–7 days (up to 10 days for musculoskeletal); avoid if contraindicated |
| Topical NSAID | Diclofenac gel 1% to affected area every 6–8 hours | 7–14 days; fewer systemic side effects than oral NSAIDs |
| Topical lidocaine | Lidocaine 5% patch to painful area (12 hours on, 12 hours off) | Musculoskeletal pain, localized neuropathic pain; max 3 patches at once |
| Muscle relaxant (if indicated) | Cyclobenzaprine 5–10 mg PO at bedtime (preferred for nighttime use due to sedation); or methocarbamol 500–750 mg PO every 6–8 hours (less sedating) | 3–7 days; avoid in elderly (delirium risk with cyclobenzaprine) |
| Gabapentinoid (if neuropathic component) | Gabapentin 100–300 mg PO at bedtime (start low); titrate by PCP | Begin at low dose; PCP follow-up for titration; not for routine use in all ED patients |
| Opioid (if needed) | Oxycodone 5 mg PO every 4–6 hours PRN severe pain; or hydrocodone/acetaminophen 5/325 mg every 4–6 hours PRN | Limit to 3 days (12–15 tablets) for most conditions; never >7 days from ED; provide with naloxone if high-risk |
8.2 Opioid-Free Discharge Alternatives
For many acute pain conditions, opioid-free discharge is both feasible and desirable. The following conditions have strong evidence supporting opioid-free management:1 16
| Condition | Opioid-Free Regimen | Evidence |
|---|---|---|
| Acute low back pain | Ibuprofen 400–600 mg + acetaminophen 1000 mg (alternating); cyclobenzaprine 5–10 mg at bedtime; heat application; early mobilization | RCTs show opioids do not improve functional outcomes in acute low back pain; opioid-free regimens have equal analgesia with fewer side effects |
| Sprains and strains | Ibuprofen + acetaminophen; topical diclofenac; ice/compression/elevation; early physical therapy | Opioids not indicated; multimodal non-opioid approach provides equivalent or superior pain relief |
| Dental pain | Ibuprofen 400–600 mg + acetaminophen 1000 mg (taken together) | This combination is superior to any opioid combination for dental pain (systematic review evidence); NNT ~1.6 for ibuprofen + acetaminophen vs. ~4.6 for hydrocodone/acetaminophen |
| Headache | Naproxen 500 mg + acetaminophen; triptan (sumatriptan 100 mg PO) if migraine not yet tried; antiemetic PRN | Opioid discharge for headache associated with increased return visits and medication overuse headache |
| Minor fractures (stable, non-operative) | Ibuprofen 400–600 mg + acetaminophen 1000 mg; proper splinting; ice; elevation | Adequate for most stable, non-operative fractures in the outpatient setting; opioid may be needed for the first 24–48 hours in some cases |
| Renal colic | Tamsulosin 0.4 mg daily + ibuprofen 600 mg every 8 hours + acetaminophen 1000 mg every 6 hours | Opioids provide no advantage for ongoing stone pain; NSAIDs are more effective for ureteral colic |
8.3 PDMP Requirements and Implementation
The Prescription Drug Monitoring Program (PDMP) is an electronic database that tracks controlled substance prescriptions. PDMP queries are mandated by law in most states before prescribing opioids.3 16
| Aspect | Detail |
|---|---|
| When to check | Before every controlled substance prescription from the ED; many states mandate PDMP query for all opioid prescriptions and all benzodiazepine prescriptions |
| What to look for | Multiple prescribers (doctor shopping); overlapping prescriptions; high total daily doses (>90 MME/day); concurrent opioid + benzodiazepine prescriptions; prescriptions from multiple pharmacies; patterns consistent with diversion |
| Red flags | ≥3 prescribers in past 3 months; ≥3 pharmacies in past 3 months; >90 MME/day; concurrent benzodiazepines; multiple early refills |
| Action on red flags | Do not withhold acute pain treatment based solely on PDMP findings; do use PDMP to guide the prescribing decision (alternatives to opioids; shorter course; lower dose); document the PDMP review and clinical decision-making; consider addiction medicine referral or social work consultation |
| ED prescribing limits | Many states limit initial opioid prescriptions to 3–7 days; ED-specific limits may be shorter; follow local policy |
8.4 Discharge Patient Education
| Topic | Key Points to Communicate |
|---|---|
| Expected pain trajectory | Pain is expected and will improve over days; the goal is functional pain control (ability to sleep, eat, move), not complete pain elimination; pain scores of 3–4 on NRS are a reasonable outpatient target |
| Medication instructions | Take scheduled non-opioids (acetaminophen, ibuprofen) around the clock for the first 2–3 days; use opioid only for breakthrough pain that is not controlled by non-opioids; take opioid with food |
| Safety | Do not drive, operate machinery, or consume alcohol while taking opioids; store medications securely away from children; dispose of unused opioids (pharmacy take-back, home disposal kits) |
| Follow-up | Return to ED for worsening pain, new symptoms, or signs of complications; schedule PCP or specialist follow-up within 3–7 days; if opioid was prescribed, follow-up should assess ongoing need |
| Naloxone education | If naloxone co-prescribed: demonstrate use to patient and companion; explain signs of overdose (slow breathing, unresponsive, blue lips); call 911 after administering naloxone |
| Non-pharmacologic strategies | Ice (20 minutes on, 20 minutes off for musculoskeletal injuries); heat (chronic muscle pain, spasm); elevation; gentle range of motion; relaxation techniques |
9. Quality Metrics and Patient Satisfaction
Pain management quality in the ED is measurable and improvable. The following metrics should be tracked as part of a continuous quality improvement program:1 17 18
9.1 Core Quality Metrics
| Metric | Target | Measurement Method |
|---|---|---|
| Time to initial pain assessment | ≤15 minutes from arrival | Triage timestamp to pain score documentation |
| Time to first analgesic | ≤30 minutes for moderate-to-severe pain (NRS ≥7) | Triage timestamp to medication administration record |
| Pain reassessment rate | ≥80% of patients with documented reassessment within 60 minutes of analgesic | Chart audit of pain score documentation |
| Multimodal analgesia rate | ≥60% of moderate-to-severe pain patients receive ≥2 non-opioid agents | Medication administration record review |
| Regional anesthesia utilization | Track and trend nerve block rates for eligible conditions (hip fracture, rib fractures) | Procedure documentation audit |
| Opioid-sparing rate | Track percentage of ED encounters managed without any opioid | Pharmacy dispensing data |
| PDMP compliance | 100% of patients receiving opioid prescriptions have documented PDMP query | Chart audit |
| Discharge pain score | ≥80% of patients with documented discharge pain score | Chart review |
| Naloxone co-prescribing rate | ≥90% of eligible high-risk patients receive naloxone co-prescription | Prescribing data audit |
| ED return for pain | <5% 72-hour return rate for pain-related revisits | Administrative data analysis |
9.2 Patient Satisfaction Considerations
| Factor | Evidence-Based Impact |
|---|---|
| Communication | Patient satisfaction with pain management correlates more strongly with how well the clinician communicated about their pain (listened to concerns, explained the plan, set expectations) than with the actual pain score achieved |
| Timeliness | Rapid time-to-analgesia is strongly associated with higher satisfaction, even if final pain scores are similar |
| Shared decision-making | Involving patients in analgesic choices (e.g., “we can try a nerve block, an IV anti-inflammatory, or a pain medication — let me explain each option”) improves satisfaction and adherence |
| Setting expectations | Explaining that the goal is functional pain control rather than zero pain reduces frustration and dissatisfaction |
| Follow-up planning | A clear discharge plan with follow-up reduces patient anxiety and ED return visits |
| Multimodal approach | Patients who receive multimodal analgesia report higher satisfaction than those receiving opioid monotherapy, even when pain scores are similar |
9.3 Continuous Quality Improvement Framework
| Element | Implementation |
|---|---|
| Data collection | Automated extraction of pain metrics from the electronic medical record; regular audit of pain assessment documentation, time-to-analgesia, and analgesic choices |
| Benchmarking | Compare departmental metrics against national benchmarks and peer institutions |
| Provider feedback | Individual and group feedback on prescribing patterns, PDMP compliance, multimodal utilization, and regional anesthesia performance |
| Education | Regular continuing medical education on pain management advances; simulation-based training for nerve blocks; procedural sedation competency maintenance |
| Protocol development | Evidence-based order sets for common pain presentations (renal colic, fracture, migraine, sickle cell); triage-initiated analgesia protocols |
| Nurse-driven protocols | Empower triage nurses to administer first-line analgesics (acetaminophen, ibuprofen) and topical anesthetics (LET gel, LMX cream) before physician evaluation |
| Patient feedback | Incorporate patient-reported outcome measures (PROMs) into quality assessment; post-discharge pain surveys |
References
Motov S, Strayer R, Hayes BD, et al. “The Treatment of Acute Pain in the Emergency Department: A White Paper Position Statement Prepared for the American Academy of Emergency Medicine.” Journal of Emergency Medicine. 2018;54(5):731-736. DOI: 10.1016/j.jemermed.2018.01.020 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chou R, Gordon DB, de Leon-Casasola OA, et al. “Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia.” Journal of Pain. 2016;17(2):131-157. DOI: 10.1016/j.jpain.2015.12.008 ↩︎ ↩︎ ↩︎ ↩︎
Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. “CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022.” MMWR Recommendations and Reports. 2022;71(RR-3):1-95. DOI: 10.15585/mmwr.rr7103a1 ↩︎ ↩︎
Pathan SA, Mitra B, Straney LD, et al. “Delivering Safe and Effective Analgesia for Management of Renal Colic in the Emergency Department: A Double-Blind, Multigroup, Randomised Controlled Trial.” Lancet. 2016;387(10032):1999-2007. DOI: 10.1016/S0140-6736(16)00652-8 ↩︎
Morrison RS, Dickman E, Hwang U, et al. “Regional Nerve Blocks Improve Pain and Functional Outcomes in Hip Fracture: A Randomized Controlled Trial.” Journal of the American Geriatrics Society. 2016;64(12):2433-2439. DOI: 10.1111/jgs.14386 ↩︎
Friedman BW, Mulvey L, Esses D, et al. “Metoclopramide for Acute Migraine: A Dose-Finding Randomized Clinical Trial.” Annals of Emergency Medicine. 2011;57(5):475-482.e1. DOI: 10.1016/j.annemergmed.2010.11.023 ↩︎
Orr SL, Friedman BW, Christie S, et al. “Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies.” Headache. 2016;56(6):911-940. DOI: 10.1111/head.12835 ↩︎
Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. “Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members.” JAMA. 2014;312(10):1033-1048. DOI: 10.1001/jama.2014.10517 ↩︎
Glassberg JA, Tanabe P, Chow A, et al. “Emergency Provider Analgesic Practices and Attitudes Toward Patients With Sickle Cell Disease.” Annals of Emergency Medicine. 2013;62(4):293-302.e10. DOI: 10.1016/j.annemergmed.2013.02.004 ↩︎
Gallagher G, Rae CP, Kinsella J. “Treatment of Pain in Severe Burns.” American Journal of Clinical Dermatology. 2000;1(6):329-335. DOI: 10.2165/00128071-200001060-00001 ↩︎ ↩︎
Fein JA, Zempsky WT, Cravero JP, et al. “Relief of Pain and Anxiety in Pediatric Patients in Emergency Medical Systems.” Pediatrics. 2012;130(5):e1391-e1405. DOI: 10.1542/peds.2012-2536 ↩︎
Borland M, Jacobs I, King B, O’Brien D. “A Randomized Controlled Trial Comparing Intranasal Fentanyl to Intravenous Morphine for Managing Acute Pain in Children in the Emergency Department.” Annals of Emergency Medicine. 2007;49(3):335-340. DOI: 10.1016/j.annemergmed.2006.06.016 ↩︎ ↩︎
Graudins A, Meek R, Egerton-Warburton D, Oakley E, Seith R. “The PICHFORK (Pain in Children Fentanyl or Ketamine) Trial: A Randomized Controlled Trial Comparing Intranasal Ketamine and Fentanyl for the Relief of Moderate to Severe Pain in Children With Limb Injuries.” Annals of Emergency Medicine. 2015;65(3):248-254.e1. DOI: 10.1016/j.annemergmed.2014.09.024 ↩︎ ↩︎
Hwang U, Belland LK, Engel KG, et al. “The Quality of Emergency Department Pain Care for Older Adult Patients.” Journal of the American Geriatrics Society. 2014;62(12):2341-2346. DOI: 10.1111/jgs.13126 ↩︎
American Geriatrics Society 2019 Beers Criteria Update Expert Panel. “American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.” Journal of the American Geriatrics Society. 2019;67(4):674-694. DOI: 10.1111/jgs.15767 ↩︎
Barnett ML, Olenski AR, Jena AB. “Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use.” New England Journal of Medicine. 2017;376(7):663-673. DOI: 10.1056/NEJMsa1610524 ↩︎ ↩︎ ↩︎
Todd KH, Ducharme J, Choiniere M, et al. “Pain in the Emergency Department: Results of the Pain and Emergency Medicine Initiative (PEMI) Multicenter Study.” Journal of Pain. 2007;8(6):460-466. DOI: 10.1016/j.jpain.2006.12.005 ↩︎
The Joint Commission. “Pain Assessment and Management Standards for Hospitals.” R3 Report Issue 11. 2017. URL: https://www.jointcommission.org/standards/r3-report/r3-report-issue-11-pain-assessment-and-management-standards-for-hospitals/ ↩︎